Sera Prognostics, Inc. (SERA) Stock Score, Valuation & Financial Research
Sera Prognostics, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 22/100.
Quick answer for SERA
Sera Prognostics, Inc. currently has a Wall Street Score of 22/100. The stored market price is $2.03. Its financial score is 12/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Sera Prognostics, Inc. does
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
SERA financial snapshot
- Wall Street Score:
- 22/100
- Current price:
- $2.03
- Market capitalization:
- $77.5M
- Revenue:
- $57K
- Net income:
- $-32.1M
- Free cash flow:
- $-26.3M
- Cash:
- $4.2M
- Total debt:
- $2.5M
- EPS:
- -0.67
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -0.3%.
- Free cash flow is $-26.3M, showing cash burn in the current stored period.
- The balance sheet shows $4.2M of cash versus $2.5M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research SERA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.